Long-Term Low-Dose Sucrose May Prevent Migraine: Two Double-Blinded Randomized Controlled Pilot Trials

Aims: To evaluate the efficacy of sucrose in the prevention of migraine attacks. Methods: Two randomized double blinded pilot trials were conducted, one in college students and one in adults. Migraineurs were randomized into two groups that each received an oral liquid: for students, sucrose 5 g/day (s-group; n = 12) or glucose 2.5 g/day (g-group; n = 10) for 3 months; and for adults, sucrose 5 g/day (s-group; n = 10) or fructose 2.5 g/day (f-group; n = 9) for 6 months. The primary endpoint was the frequency of migraine attacks per month, and the secondary endpoints were mean duration and severity of migraine per attack. Continuous measurements were described as mean ± standard deviation (SD). The overall significance of the effects between different groups was tested using repeated measures analysis of variance (RANOVA), and the efficacy was evaluated using an intent-to-treat analysis. Results: Migraine frequency in the students declined significantly in the g-group (mean reduction ± SD: 0.65 ± 0.71; P < .01), but not in the s-group (0.33 ± 2.02; P = .58). RANOVA results suggested that the secondary endpoints significantly declined over time (all P < .01) with no differences between the groups. In the adult trial, mixed-effects model analysis showed that both the primary and secondary endpoints significantly declined over time with no significant differences between the groups. Conclusion: Long-term consumption of a 5-g dose of sucrose for adult migraineurs or a 2.5g dose of glucose forcollege student migraineurs may be as effective as preventive treatments.

migraine;prevention;sucrose

1. GBD 2015 Disease and Injury Incidence and Prevalence Col- laborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: A systematic analysis for the Global Burden of Dis- ease Study 2015. Lancet 2016;388:1545–1602.

2. Breslau N, Rasmussen BK. The impact of migraine: Epide- miology, risk factors, and co-morbidities. Neurology 2001; 56(6 suppl 1):S4–S12.

3. Cirillo M, Stellato D, Lombardi C, De Santo NG, Covelli V. Head- ache and cardiovascular risk factors: Positive association with hypertension. Headache 1999;39:409–416.

4. Etminan M, Takkouche B, Isorna FC, Samii A. Risk of isch- aemic stroke in people with migraine: Systematic review and meta-analysis of observational studies. BMJ 2005;330:63.

5. Silberstein S D, Holland S, Freitag F, et al. Evidence-based guideline update: Pharmacologic treatment for episodic mi- graine prevention in adults: Report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 2012;78:1337–1345.

6. Boehnke C, Reuter U, Flach U, Schuh-Hofer S, Einhäupl KM, Arnold G. High-dose riboflavin treatment is efficacious in mi- graine prophylaxis: An open study in a tertiary care centre. Eur J Neurol 2004;11:475–477.

7. Maizels M, Blumenfeld A, Burchette R. A combination of ribo- flavin, magnesium, and feverfew for migraine prophylaxis: A ran- domized trial. Headache 2004;44:885–890.

8. Choi H, Parmar N. The use of intravenous magnesium sulphate for acute migraine: Meta-analysis of randomized controlled tri- als. Eur J Emerg Med 2014;21:2–9.

9. MacLennan SC, Wade FM, Forrest KM, Ratanayake PD, Fa- gan E, Antony J. High-dose riboflavin for migraine prophylaxis in children: A double-blind, randomized, placebo-controlled trial. J Child Neurol 2008;23:1300–1304.

10. Powers SW, Coffey CS, Chamberlin LA, et al. Trial of amitrip- tyline, topiramate, and placebo for pediatric migraine. N Engl J Med 2017;376:115–124.

11. Kelman L. The triggers or precipitants of the acute migraine at- tack. Cephalalgia 2007;27:394–402.

12. Ierusalimschy R, Moreira Filho PF. Precipitating factors of mi- graine attacks in patients with migraine without aura [in Portu- guese]. Arq Neuropsiquiatr 2002;60:609–613.

13. Critchley M. Migraine. Lancet 1933;1:123–126.

14. Jacome DE. Hypoglycemia rebound migraine. Headache 2001; 41:895–898.

15. GrayP,BurtnessH.Hypoglycemicheadache.Endocrinology1935;19:549–560.

16. Blau JN, Pyke DA. Effect of diabetes on migraine. Lancet 1970; 2:241–243.

17. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004;24(suppl 1):s9–s160.

18. Tfelt-Hansen P, Pascual J, Ramadan N, et al. Guidelines for controlled trials of drugs in migraine: A guide for investigators. Cephalalgia 2012;32:6–38.

19. Macedo A, Baños JE, Farré M. Placebo response in the prophy- laxis of migraine: A meta-analysis. Eur J Pain 2008;12:68–75.

20. Luo N, Di W, Zhang A, et al. A randomized, one-year clinical trial comparing the efficacy of topiramate, flunarizine, and a combi- nation of flunarizine and topiramate in migraine prophylaxis. Pain Med 2012;13:80–86.

21. Nambiar NJ, Aiyappa C, Srinivasa R. Oral riboflavin versus oral propranolol in migraine prophylaxis: An open label randomized controlled trial. Neurol Asia 2011;16:223–229.

22. Schoenen J, Jacquy J, Lenaerts M. Effectiveness of high-dose riboflavin in migraine prophylaxis. A randomized controlled trial. Neurology 1998;50:466–470.

23. Guo Y, Han X, Yu T, Yao G. Meta-analysis of efficacy of topiramate in migraine prophylaxis. Neural Regen Res 2012;7:1806–1811.

24. Ashrafi MR, Najafi Z, Shafiei M, Heidari K, Togha M. Cinnarizine versus topiramate in prophylaxis of migraines among children and adolescents: A randomized, double-blind clinical trial. Iran J Child Neurol 2014;8:18–27.

25. Stanhope KL, Schwarz JM, Keim NL, et al. Consuming fruc- tose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans. J Clin Invest 2009;119:1322–1334.

26. Schoenen J, Lenaerts M, Bastings E. High-dose riboflavin as a prophylactic treatment of migraine: Results of an open pilot study. Cephalalgia 1994;14:328–329.

27. Pearce J. Insulin induced hypoglycaemia in migraine. J Neurol Neurosurg Psychiatry 1971;34:154–156.

28. Aamodt AH, Stovner LJ, Midthjell K, Hagen K, Zwart JA. Head- ache prevalence related to diabetes mellitus. The Head-HUNT study. Eur J Neurol 2007;14:738–744.

29. Berge LI, Riise T, Fasmer OB, et al. Does diabetes have a pro- tective effect on migraine? Epidemiology 2013;24:129–134.

30. Relief of Pain. A Medical Discovery. Islamic Voice 2001;15(172). https://www.islamicvoice.com/april.2001/quran.htm. Accessed 20 November, 2018.

31. Stevens B, Yamada J, Ohlsson A, Haliburton S, Shorkey A. Su- crose for analgesia in newborn infants undergoing painful pro- cedures. Cochrane Database Syst Rev 2016;7:CD001069.

32. Slater R, Cornelissen L, Fabrizi L, et al. Oral sucrose as an anal- gesic drug for procedural pain in newborn infants: A randomised controlled trial. Lancet 2010;376:1225–1232.

33. Harrington JW. Sugar and warmth additively decrease pain in newborns getting vaccines. Evid Based Med 2015;20:125.

34. Cook LM, Nichols-Dada J, Damani S, et al. Randomized clinical trial of 24% oral sucrose to decrease pain associated with pe- ripheral intravenous catheter insertion in preterm and term new- borns. Adv Neonatal Care 2017;17:E3–E11.

35. Harrison D, Larocque C, Reszel J, Harrold J, Aubertin C. Be sweet to babies during painful procedures: A pilot evaluation of a parent-targeted video. Adv Neonatal Care 2017;17:372–380.

36. Goksan S, Hartley C, Emery F, et al. Correction: fMRI reveals neural activity overlap between adult and infant pain. Elife 2015; 4:e08663.

37. Ranger M, Grunau RE. How do babies feel pain? Elife 2015; 4:e07552.

38. Apkarian A V, Hashmi JA, Baliki MN. Pain and the brain: Speci- ficity and plasticity of the brain in clinical chronic pain. Pain 2011; 152(3 suppl):s49–s64.

39. Anseloni VC, Ren K, Dubner R, Ennis M. A brainstem sub- strate for analgesia elicited by intraoral sucrose. Neuroscience 2005;133:231–243.

40. Ren K, Blass EM, Zhou Q, Dubner R. Suckling and sucrose ingestion suppress persistent hyperalgesia and spinal Fos ex- pression after forepaw inflammation in infant rats. Proc Natl Acad Sci U S A 1997;94:1471–1475.

41. Anseloni VC, Weng HR, Terayama R, et al. Age-dependency of analgesia elicited by intraoral sucrose in acute and persistent pain models. Pain 2002;97:93–103.